抗精神病药治疗精神分裂症疗效与异质性的荟萃分析
结果显示抗精神病药总体症状改善优于安慰剂(Hedges' g=0.47,p<0.001),且总症状、阳性症状和阴性症状改善的变异系数比均降低。个体患者数据未见双峰分布,不支持存在抗精神病药无反应亚型。
要点
- 抗精神病药急性期治疗精神分裂症总体症状改善优于安慰剂(g=0.47,p<0.001)
- 抗精神病药组总症状、阳性及阴性症状改善的变异均低于安慰剂组
- 个体患者数据未发现双峰分布,不支持抗精神病药无反应亚型假说
核心结论
- 抗精神病药治疗精神分裂症症状改善优于安慰剂且变异更低,不支持存在抗精神病药无反应亚型。
研究设计与样本
- 系统检索PubMed、EMBASE和PsycINFO自建库至2018年11月30日的随机对照试验。
- 另分析两项临床试验的个体患者数据(N=522例)。
主要发现
- 抗精神病药组总症状改善优于安慰剂(Hedges' g=0.47,p<0.001)。
- 总症状(CVR=0.86,p<0.001)、阳性症状(CVR=0.89,p<0.001)和阴性症状(CVR=0.86,p=0.001)改善的变异系数比均降低。
- 抗精神病药反应变异较低与更早发表的研究(z=3.98,p<0.001)、更年轻患者(z=3.07,p=0.002)、更高剂量治疗(z=-2.62,p=0.009)和更大平均症状变化差异(z=-5.70,p<0.001)相关。
- 个体患者数据中抗精神病药治疗未显示任何单个症状变异显著增加,无证据支持反应呈双峰分布。
关键数值与推荐
- 总症状改善的Hedges' g=0.47(p<0.001),CVR=0.86(p<0.001)。
- 阳性症状CVR=0.89(p<0.001),阴性症状CVR=0.86(p=0.001)。
临床怎么用
- 临床可预期抗精神病药对精神分裂症症状改善相对均一,无需常规按治疗反应划分亚型。
- 治疗选择仍应基于个体化评估,但不应预设存在固有的抗精神病药无反应亚型。
局限性
- 纳入研究异质性可能影响结果,如发表年份、患者年龄和剂量差异。
- 个体患者数据仅来自两项临床试验,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The response to antipsychotic treatment in schizophrenia appears to vary, and as such it has been proposed that different subtypes of schizophrenia exist, defined by treatment-response. This has not been formally examined using meta-analysis. Randomised controlled trials comparing placebo and antipsychotics in acute treatment of schizophrenia listed in PubMed, EMBASE and PsycINFO from inception until 30 November 2018 were examined. Relative variability of symptomatic improvement in antipsychotic-treated individuals compared to placebo-treated individuals was quantified using coefficient of variation ratio (CVR). Mean difference in symptom change was quantified using Hedges' g. In addition, individual patient data from two clinical trials was examined in terms of both the distribution of total symptom change, and the variability of individual symptoms and symptom factors. In total, 11,006 articles were identified. Sixty six met inclusion criteria, reporting on 17,202 patients. Compared with placebo, antipsychotic-treated patients demonstrated greater total symptom improvement (g = 0.47, p < 0.001) and reduced variability in symptomatic improvement for total (CVR = 0.86, p < 0.001), positive (CVR = 0.89, p < 0.001), and negative symptoms (CVR = 0.86, p = 0.001). Lower variability in antipsychotic-response relative to placebo was associated with studies published earlier (z = 3.98, p < 0.001), younger patients (z = 3.07, p = 0.002), higher dose treatments (z = -2.62, p = 0.009), and greater mean-difference in symptom-change (z = -5.70, p < 0.001). In the individual patient dataset (N = 522 patients), antipsychotic treated patients did not show significantly increased variability for any individual symptom, and there was no evidence of a bimodal distribution of response. Compared to placebo, antipsychotic treatment shows greater improvement and lower variability of change in total, positive and negative symptoms. This is contrary to the hypothesis that there is a subtype of antipsychotic non-responsive schizophrenia. Instead our findings, provide evidence for a relatively homogeneous effect of antipsychotic treatment in improving symptoms of schizophrenia.
引用
- McCutcheon RA, Pillinger T, Mizuno Y, et al. The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis. Mol Psychiatry. 2019. PMID: 31471576. doi:10.1038/s41380-019-0502-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。